secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001689375-24-000061
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q3 net loss $14.0M; advancing DMD franchise with regulatory filings on track
--------------------------------------------------------------------------------

- Net loss $14.0M in Q3 2024 (vs $35.5M net income in Q3 2023); revenue down to $19.6M from $43.7M.
- Cash $449.3M as of Sep 30, 2024, up from $352.0M at end of 2023; funded by $100M offering and $75M milestone.
- R&D expenses $31.3M (vs $22.2M) driven by DMD candidates; G&A $10.0M (vs $7.5M).
- On track to submit global regulatory filings for Phase 2 trials of ENTR-601-44 and ENTR-601-45 in Q4 2024.
- Vertex completed SAD and initiated MAD for VX-670 in DM1; Sethuraman promoted to President of R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000061/0001689375-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000061/trda-20241105.htm
  HTML page:      https://secwatch.observer/filing/0001689375-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer